CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

August 26, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

Sub: <u>Intimation of receipt of In-principle Approval from National Stock Exchange of India Limited for issuance of Equity Shares on Right Issue.</u>

Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Anondita Medicare Limited ("the Company") has received the In-Principle Approval from the National Stock Exchange of India Limited ("NSE") for the proposed Rights Issue of fully paid-up Equity Shares of face value of ₹10/- each, aggregating up to ₹10,978.20 lakhs, **vide its letter bearing reference No. NSE/LIST/C/2026/0866 dated August 25, 2026.**

A copy of the In-Principle Approval letter received from NSE is enclosed herewith for your information and records.

The details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed herewith as **Annexure - A**.

We request you to take the same on your record.

Thanking You.
Yours faithfully,

For and on behalf of
ANONDITA MEDICARE LIMITED

BHAWNA BISHT
Digitally signed by BHAWNA BISHT
Date: 2026.08.26 11:10:06 +05'30'

Bhawna Bisht
Company Secretary and Compliance Officer
M No : A70843
Encl: As above

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

Annexure – A

<u>Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with Schedule III and SEBI Master Circular No. SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.</u>

S. No.	Particulars	Details
1.	**Name of the regulatory or licensing authority;**	National Stock Exchange of India Limited ("NSE")
2.	**Brief details of the approval/licenseobtained/ withdrawn/ surrendered;**	In – Principle approval granted by NSE for issuance of fully paid up equity shares on right basis
3.	**Impact/relevance of such approval/license to the listed entity;**	Upon receipt of In-Principle approvals, the Company is permitted to issue and allot fully paid-up equity share of the Company, having a face value of Rs. 10/-, on a Rights basis, subject to applicable laws and regulatory approvals.
4.	**Withdrawal/cancellation or suspension of licence/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any;**	Not Applicable
5.	**Period for which such approval/license is/was valid;**	As per the relevant applicable provisions
6.	**The actual impact (monetary or otherwise) along with corrective actions taken by the listed entity pursuant to the withdrawal, cancellation or suspension of the key license/ approval.**	Not Applicable

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

Ref. No: NSE/LIST/C/2026/0866 August 25, 2026

The Company Secretary,
Anondita Medicare Limited

Dear Sir/Madam,

Sub: Proposed Rights issue of up to [●] Fully Paid Equity shares of Rs. 10/- each.

We are in receipt of application regarding in-principle approval for proposed issue of up to [●] Fully paid equity shares of face value of Rs. 10/- each of the Company for cash at a price of [●] per rights equity share (including a premium of Rs. [●] per rights equity share), aggregating up to Rs. 10978.20 lakhs on a rights basis to the eligible equity shareholders of the company in the ratio of [●] rights Equity for every [●] equity shares held by the eligible equity shareholders of the company on the record date.

In this regard, the Exchange is pleased to grant in-principle approval for issue, subject to the Company fulfilling the following conditions:

1. Filing the listing application at the earliest from the date of allotment.
2. Receipt of statutory and other approvals and compliance of guidelines/regulations issued by the statutory authorities including SEBI, RBI, MCA, etc.
3. Compliance with all the guidelines, regulations, directions of the Exchange or any statutory authorities, documentary requirements from time to time.
4. Compliance of all conditions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as on date of listing.
5. Compliance of the Companies Act, 1956 / Companies Act, 2013 and other applicable laws.

The Exchange reserves its right to withdraw its in-principle approval at a later stage if the information submitted to the Exchange is found to be incomplete/incorrect/misleading/false or in contravention of any Rules, Bye-laws and Regulations of the Exchange and Securities Laws.

You have been permitted to use the name of the National Stock Exchange of India Limited in the Letter of Offer in respect of the proposed rights issue provided the Company prints the Disclaimer Clause as given below in the offer document after the SEBI disclaimer clause.

"As required, a copy of this letter of offer has been submitted to National Stock Exchange of India Limited (hereinafter referred to as NSE). NSE has given vide its letter Ref. No. NSE/LIST/C/2026/0866 dated August 25, 2026, permission to the Issuer to use the Exchange's name in this letter of offer as one of the stock exchanges on which this Issuer's securities are proposed to be listed. The Exchange has scrutinized this letter of offer for its limited internal purpose of deciding on the matter of granting the aforesaid permission to this Issuer.

It is to be distinctly understood that the aforesaid permission given by NSE should not in any way be deemed or construed that the letter of offer has been cleared or approved by NSE; nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the contents of this letter of offer; nor does it warrant that this Issuer's securities will be listed or will continue to be listed on the Exchange; nor does it take any responsibility for the financial or other soundness of this Issuer, its promoters, its management or any scheme or project of this Issuer.

This Document is Digitally Signed

Signed by: Ankita Gupta
Date: Tue, Aug 25, 2026 17:49:30 IST
Location: NSE

Ref. No: NSE/LIST/C/2026/0866 August 25, 2026

Every person who desires to apply for or otherwise acquire any securities of this Issuer may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription /acquisition whether by reason of anything stated or omitted to be stated herein or any other reason whatsoever."

You may insert the following lines in the advertisements instead of the entire disclaimer clause:

"It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the letter of offer has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the letter of offer. The investors are advised to refer to the letter of offer for the full text of the 'Disclaimer Clause of NSE".

Kindly note that the Exchange will issue approval for listing and trading of equity shares subject to the compliances as stated above. The Company should not take any steps to dematerialize any of the securities except rights entitlement pursuant to the in – principle approval given in this letter by the Exchange, until further notice.

Kindly note, this Exchange letter should not be construed as approval under any other Act / Regulation/ rule/bye laws (except as referred above) for which the Company may be required to obtain approval from other department(s) of the Exchange. The Company is requested to separately take up matter with the concerned departments for approval, if any.

The company is hereby advised that the ratio in which the shares are proposed to be issued on a rights basis may not create any odd lots.

Yours faithfully,
For National Stock Exchange of India Limited

Ankita Gupta
Manager

cc:

Lead Managers to the Issue	**Registrar to the Issue**
NA	Skyline Financial Services Private Limited

Depositories	
National Securities Depository Limited	**Central Depository Services Limited**

P.S. Checklist of all the further issues is available on website of the exchange at the following URL:
https://www.nseindia.com/companies-listing/raising-capital-further-issues-main-sme-checklist

The National Stock Exchange of India (NSE) has announced the launch of NEAPS mobile application. The app can be downloaded from the App Store/ Play store with the name "NEAPS APP"

This Document is Digitally Signed

Signed by: Ankita Gupta
Date: Tue, Aug 25, 2026 17:49:30 IST
Location: NSE